A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg

References

• Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest 2005;115:200–8
   PubMed Web of Science ®Google Scholar
• Altman RD. Paget’s disease of bone. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism, 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 985–1020
   Google Scholar
• Siris ES, Roodman GD. Paget’s disease of bone. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism,5th ed. Washington (DC): American Society for Bone and Mineral Research; 2003. p. 495–506
   Google Scholar
• Langston AL, Ralston SH. Management of Paget’s disease of bone. Rheumatology 2004;43:955–9
   PubMed Web of Science ®Google Scholar
• Selby PL, Davie MWJ, Ralston SH, Stone MD. Guidelines on the management of Paget’s disease of bone. Bone 2002;31:366–73
   PubMed Web of Science ®Google Scholar
• Ankrom MA, Shapiro JR. Paget’s disease of bone (osteitis deformans). J Am Geriatr Soc 1998;46:1025–33
   PubMed Web of Science ®Google Scholar
• Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res 2001;16:1379–87
   PubMed Web of Science ®Google Scholar
• Cooper C, Schafheutle K, Dennison E, et al. The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999;14:192–7
   PubMed Web of Science ®Google Scholar
• Cundy HR, Gamble G, Wattie D, et al. Paget’s disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 2004;75:358–64
   PubMed Web of Science ®Google Scholar
• Poór G, Donath J, Fornet B, Cooper C. Epidemiology of Paget’s disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006;21:1545–9
   Google Scholar
• Mirón-Canelo JA, Del Pino-Montes J, Vicente-Arroyo M, Sälenz-Gonzälez MC; the Paget’s disease of the bone group of Salamanca. Epidemiological study of Paget’s disease of bone in a zone of the province of Salamanca (Spain). Eur J Epidemiol 1997;13:801–5
   Google Scholar
• Leach RJ, Singer FR, Cody JD, Roodman GD. Variable disease severity associated with a Paget’s disease predisposition gene. J Bone Miner Res 1999;14:17–20
   PubMed Web of Science ®Google Scholar
• Cody JD, Singer FR, Roodman GD, et al. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997;61:1117–22
   PubMed Web of Science ®Google Scholar
• Haslam SI, Van Hul W, Morales-Piga A, et al. Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 1998;13: 911–7
   Google Scholar
• Cavey JR, Ralston SH, Hocking LJ, et al. Loss of ubiquitin-binding associated with Paget’s disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005;20:619–24
   PubMed Web of Science ®Google Scholar
• Cavey JR, Ralston SH, Sheppard PW, et al. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget’s disease of bone. Calcif Tissue Int 2006;78:271–7
   PubMed Web of Science ®Google Scholar
• Hocking LJ, Lucas GJA, Daroszewska A, et al. Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004;19:1122–7
   PubMed Web of Science ®Google Scholar
• Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002;70:1582–8
   PubMed Web of Science ®Google Scholar
• Rebel A, Malkani K, Basle M, et al. Ultrastructural characteristics of osteoclasts in Paget’s disease. Rev Rhum Mal Osteoartic 1974;41:767–71
   PubMedGoogle Scholar
• Mii Y, Miyauchi Y, Honoki K, et al. Electron microscopic evidence of a viral nature for osteoclast inclusions in Paget’s disease of bone. Virchows Arch 1994;424:99–104
   PubMed Web of Science ®Google Scholar
• Ralston SH, Helfrich MH. Are paramyxoviruses involved in Paget’s disease? A negative view. Bone 1999;24(Suppl):17S–18S
   Google Scholar
• Hoyland JA, Freemont AJ, Sharpe PT. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget’s disease. J Bone Miner Res 1994;9: 75–80
   Google Scholar
• Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget’s disease. QJM 2002;95:233–40
   PubMed Web of Science ®Google Scholar
• Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin 6: a potential autocrine/paracrine factor in Paget’s disease of bone. J Clin Invest 1992;89:46–52
   PubMed Web of Science ®Google Scholar
• Kanis JA. Clinical features and complications. In: Kanis JA, editor. Pathophysiology and treatment of Paget’s disease of bone. London (UK): Martin Dunitz; 1998. p. 110–38
   Google Scholar
• Briesacher BA, Orwig D, Seton M, et al. Medical care costs of Paget’s disease of bone in a privately insured population. Bone 2006;38:731–7
   PubMed Web of Science ®Google Scholar
• Herzberg L, Bayliss E. Spinal-cord syndrome due to non-compressive Paget’s disease of bone: a spinal-artery steal phenomenon reversible with calcitonin. Lancet 1980;2:13–5
   PubMed Web of Science ®Google Scholar
• Eisman JA, Martin TJ. Osteolytic Paget’s disease: recognition and risks of biopsy. J Bone Joint Surg Am 1986;68:112–7
   PubMedGoogle Scholar
• Delmas PD, Meunier PJ. The management of Paget’s disease of bone. New Engl J Med 1997;336:558–66
   PubMed Web of Science ®Google Scholar
• Eastell R. Biochemical markers of bone turnover in Paget’s disease of bone. Bone 1999;24(Suppl):49S–50S
   Google Scholar
• Ralston SH, Boyce BF, Cowan RA, et al. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget’s disease – a double-blind randomized clinical study. J Bone Miner Res 1987;2:5–12
   PubMed Web of Science ®Google Scholar
• Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget’s disease of bone: a double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum 1992;35:967–74
   PubMed Web of Science ®Google Scholar
• Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996;101:341–8
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. New Engl J Med 2005;353:898–908
   PubMed Web of Science ®Google Scholar
• Kurtzweil P. Help for people with Paget’s disease. FDA Consumer. 1996;30. Available at http://www.fda.gov/fdac/features/896_pag.html [accessed February 12, 2007]
   Google Scholar
• Meunier PJ, Vignot E. Therapeutic strategy in Paget’s disease of bone. Bone 1995;17(Suppl):489S–491S
   Google Scholar
• Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget’s disease of bone. J Bone Miner Res 1993;8:1467–73
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235–42
   PubMed Web of Science ®Google Scholar
• Frith JC, Mönkkönen J, Auriola S, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201–10
   PubMed Web of Science ®Google Scholar
• Actonel® [prescribing information]. Cincinnati (OH): Procter & Gamble Pharmaceuticals, Inc.: May 2007
   Google Scholar
• Didronel® [prescribing information]. Cincinnati (OH): Procter & Gamble Pharmaceuticals, Inc.: May 2005
   Google Scholar
• Fosamax® [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc.: December 2006
   Google Scholar
• Skelid® [prescribing information]. Bridgewater (NJ): Sanofi-Aventis: April 2006
   Google Scholar
• Aredia® [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation: February 2007
   Google Scholar
• Reclast® [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; April 2007
   Google Scholar
• Fogelman I, Smith L, Mazess R, et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986;24:57–62
   PubMed Web of Science ®Google Scholar
• Roux C, Dougados M. Treatment of patients with Paget’s disease of bone. Drugs 1999;58:823–30
   PubMed Web of Science ®Google Scholar
• Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 1977;44:96–106
   PubMed Web of Science ®Google Scholar
• Fraser WD, Stamp TC, Creek RA, et al. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget’s disease of bone. Postgrad Med J 1997;73:496–502
   PubMed Web of Science ®Google Scholar
• Miller PD, Brown JP, Siris ES, et al.; for the Paget’s Risedronate/ Etidronate Study Group. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 1999;106:513–20
   Google Scholar
• Rendina D, Mossetti G, Viceconti R, et al. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int 2004;75:189–96
   PubMed Web of Science ®Google Scholar
• Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget’s disease of bone. Arthritis Rheum 1995;38:851–8
   PubMed Web of Science ®Google Scholar
• Russell RG, Smith R, Preston C, et al. Diphosphonates in Paget’s disease. Lancet 1974;1:894–8
   PubMed Web of Science ®Google Scholar
• Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 1998;13:1032–8
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617–27
   PubMed Web of Science ®Google Scholar
• Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745–51
   PubMed Web of Science ®Google Scholar
• Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002;55:210–24
   Web of Science ®Google Scholar
• Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142–8
   PubMed Web of Science ®Google Scholar
• Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget’s disease of bone. Bone 2006;39:954–8
   Google Scholar
• Black DM, Delmas PD, Eastell R, et al.; for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007;356:1809–22
   Google Scholar